Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081224 | 1.00 | SIGMAR1 (0.47) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL18878794 | 0.84 | GAA (0.68) | GAAOPRM1CYP3A4CYP2D6KDM4E | |
| SCHEMBL18878793 | 0.82 | SIGMAR1 (0.45) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL19199626 | 0.80 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL16444908 | 0.80 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL24538638 | 0.80 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL18229424 | 0.80 | GAA (0.72) | SIGMAR1GAAOPRM1CYP3A4CYP2D6 | |
| SCHEMBL18714586 | 0.77 | OPRM1 (0.60) | OPRM1OPRD1 | |
| SCHEMBL18994802 | 0.77 | OPRM1 (0.60) | OPRM1OPRD1 | |
| SCHEMBL21081252 | 0.76 | OPRM1 (0.46) | SIGMAR1OPRM1CYP3A4CYP2D6MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | SIGMAR1 1138/4885GAA 398/4885OPRM1 159/4885 |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | SIGMAR1 1138/4885GAA 398/4885OPRM1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.